Positive minimal residual disease of FLT3-ITD before hematopoietic stem cell transplantation resulted in a poor prognosis of an acute myeloid leukemia

Yuka Iwasaki, Rituo Nishiuchi, Michinori Aoe, Takahide Takahashi, Hirokazu Watanabe, Chiho Tokorotani, Kiyoshi Kikkawa, Akira Shimada

Research output: Contribution to journalArticle

2 Citations (Scopus)


Acute myeloid leukemia (AML) patients with fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) often have a poor prognosis, even after hematopoietic stem cell transplantation (HSCT). We report a case of AML with FLT3-ITD identified upon initial diagnosis, who received HSCT at complete remission after 3 consecutive chemotherapies. However, the patient relapsed when the same FLT3-ITD clone emerged, and finally died. Retrospective analysis revealed an allelic ratio of FLT3-ITD/wild type of 1.1 and 0.0096 upon initial diagnosis and before HSCT, respectively. The detection of any minimal residual FLT3-ITD clone before HSCT is useful in the treatment of AML with FLT3-ITD.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalActa Medica Okayama
Issue number1
Publication statusPublished - 2017



  • Acute myeloid leukemia
  • FLT3-ITD
  • HSCT
  • Minimal residual disease
  • Relapse

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this